Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages (Q39957547)

15 September 2017

Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages (English)

1 reference

15 September 2017

0 references

Emilie Velot

1

1 reference

15 September 2017

Benjamin Haas

2

1 reference

15 September 2017

Frédérique Léonard

3

1 reference

15 September 2017

Isabelle Ernens

4

1 reference

15 September 2017

Magali Rolland-Turner

5

1 reference

15 September 2017

Chantal Schwartz

6

1 reference

15 September 2017

Dan Longrois

7

1 reference

15 September 2017

Yvan Devaux

8

1 reference

15 September 2017

Daniel R Wagner

9

1 reference

15 September 2017

24 July 2008

1 reference

15 September 2017

Cardiovascular Research

1 reference

15 September 2017

80

1 reference

15 September 2017

246-254

1 reference

15 September 2017

2

1 reference

Vital epidemiologic clues in heart failure

15 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Long-Term Trends in the Incidence of and Survival with Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Adenosine receptors as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Adenosine-mediated cardioprotection in the aging myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Adenosine modulation of tumor necrosis factor-alpha-induced neutrophil activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Hypoxia suppresses the production of MMP-9 by human monocyte-derived dendritic cells and requires activation of adenosine receptor A2b via cAMP/PKA signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Pivotal advance: endogenous pathway to SIRS, sepsis, and related conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

TLR4 activation mediates kidney ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Broad-spectrum cardioprotection with adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Intravenous adenosine and lidocaine in patients with acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN201

21 January 2018

Identifiers

DOI

10.1093/CVR/CVN201

1 reference

15 September 2017

1 reference